Free Trial

Regulus Therapeutics Q4 2022 Earnings Report

Regulus Therapeutics logo
$1.53 -0.06 (-3.77%)
(As of 05:45 PM ET)

Regulus Therapeutics EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.49
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Regulus Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Regulus Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A
Mysterious drone activity triggers massive 1,366% surge (Ad)

If mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.

👉 Click here now to see how this signal works.

Regulus Therapeutics Earnings Headlines

A brand new opportunity in the stock market revealed
Today, I want to unlock a brand new opportunity in the stock market… One that has been able to pay out around 100% in 5 days or less so far on REAL money… It’s all thanks to a hidden force that drives some of the BIGGEST & most repetitive moves in stocks… I call it a Gamma Pocket…
Regulus Therapeutics Reports Q3 2024 Financial Results
See More Regulus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Regulus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regulus Therapeutics and other key companies, straight to your email.

About Regulus Therapeutics

Regulus Therapeutics (NASDAQ:RGLS), a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

View Regulus Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings